Processing Your Payment
Please do not leave this page until complete. This can take a few moments.
-
News
- Editions
- Lists
-
Viewpoints
-
HBJ Events
-
Event Info
- What's Your Story? A Small Business Giveaway 2025 Presented By: Torrington Savings Bank
- Best Places to Work in Connecticut 2025
- Women In Business Awards 2025
- Connecticut's Family Business Awards 2025
- 40 Under Forty Awards 2025
- C-Suite and Lifetime Achievement Awards 2025
- Connecticut's Health Care Heroes Awards 2025
-
-
Business Calendar
-
Custom Content
- News
-
Editions
View Digital Editions
Biweekly Issues
- March 10, 2025
- Feb. 24, 2025
- Feb. 10, 2025
- Jan. 27, 2025
- Jan. 13, 2025
- Dec. 9, 2024
- Nov. 25, 2024
- Nov. 11, 2024
- Oct. 28, 2024
- + More
Special Editions
- Lists
- Viewpoints
-
HBJ Events
Event Info
- View all Events
- What's Your Story? A Small Business Giveaway 2025 Presented By: Torrington Savings Bank
- Best Places to Work in Connecticut 2025
- Women In Business Awards 2025
- Connecticut's Family Business Awards 2025
- 40 Under Forty Awards 2025
- C-Suite and Lifetime Achievement Awards 2025
- Connecticut's Health Care Heroes Awards 2025
Award Honorees
- Business Calendar
- Custom Content
Bioscience
CT Commerce Committee considers R&D tax credit for pass-through entities
David Krechevsky March 6, 2025Pass-through business entities with research and development expenses would receive a tax credit under a bill being considered by state lawmakers.
David Krechevsky March 6, 2025
BioXcel Therapeutics raises $14M in direct offering
David Krechevsky March 5, 2025BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company, said it has raised $14 million from a registered direct offering.
David Krechevsky March 5, 2025-
New Haven-based BioXcel avoids delisting from Nasdaq stock exchange
David Krechevsky February 28, 2025Just three weeks after executing a 1-for-16 reverse stock split of its common stock, New Haven-based biopharmaceutical company BioXcel Therapeutics Inc. on Friday announced it has avoided being delisted from the Nasdaq stock market.
David Krechevsky February 28, 2025 
New Haven-based biotech Rallybio faces delisting from Nasdaq
David Krechevsky February 27, 2025Rallybio, a New Haven-based biotechnology firm, notified federal regulators this week that it faces delisting from the Nasdaq Stock Market.
David Krechevsky February 27, 2025
Proposed R&D tax credit boost 'a huge win' for CT bioscience firms
David Krechevsky February 24, 2025When Gov. Ned Lamont addressed BioCT’s 2025 legislative breakfast on Jan. 27 in New Haven, his keynote address included a surprise.
David Krechevsky February 24, 2025-
Despite setbacks, investors remain bullish on CT’s bioscience sector, but changes in Washington raise uncertainty
David Krechevsky February 24, 2025The state’s bioscience sector is a lot like that box of chocolates in the film “Forrest Gump” — you never know what you’re going to get. Several state-based companies have recently suffered significant financial woes:
David Krechevsky February 24, 2025
CT drugmaker in ‘advanced talks’ to be acquired by Germany’s Merck
Andrew Larson February 11, 2025Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and cancer, is in “advanced talks” to be acquired by Germany’s Merck, according to Reuters.
Andrew Larson February 11, 2025
CT joins states suing Trump over health research funding cuts
Katy Golvala, CT Mirror February 11, 2025Connecticut and 21 other states jointly sued the federal government on Monday over the administration’s move to slash funding provided to research institutions through the National Institutes of Health.
Katy Golvala, CT Mirror February 11, 2025
Guilford biotech to cut 14% of workforce amid widening losses
Andrew Larson, Greg Bordonaro January 29, 2025Biotechnology firm Hyperfine Inc., an emerging growth company based in Guilford, announced Wednesday that it is cutting about 14% of its global workforce amid widening losses.
Andrew Larson, Greg Bordonaro January 29, 2025
Legislative proposals seek to expand economic development zones in Plainville
David Krechevsky January 24, 2025Two bills proposed in the 2025 legislative session seek to create or expand economic development zones in the town of Plainville.
David Krechevsky January 24, 2025
Westport AI biotech company gets $4M investment
Harriet Jones January 21, 2025A Westport-based startup that applies artificial intelligence to biomedical research has received a $4 million investment.
Harriet Jones January 21, 2025
CT regulator agrees to settlement allowing $96M proton therapy cancer center in Danbury
David Krechevsky January 17, 2025State health regulators said Friday they have reached an agreement that will allow for the development of a second proton beam therapy center in Connecticut.
David Krechevsky January 17, 2025
Branford biopharma firm Azitra prices $1.5M public stock offering
David Krechevsky January 17, 2025Azitra Inc., a Branford-based biopharmaceutical firm, has announced the pricing for a public offering of its common stock.
David Krechevsky January 17, 2025
Boston/New Haven-based biotech closes $75M in Series B financing
David Krechevsky January 13, 2025Normunity Inc., a biotech creating anti-cancer immunotherapies, announced Monday it has closed a $75 million Series B financing round.
David Krechevsky January 13, 2025
New Haven-based biotech raises $14.5M to expand PTSD treatment program
Andrew Larson January 10, 2025A New Haven-based biotech company, Nema Health, announced a $14.5 million Series A funding round that will expand its online trauma therapy program to three new states: California, Florida and Pennsylvania.
Andrew Larson January 10, 2025
CT biotech firm secures $9M to advance oral treatment for inflammatory bowel disease
Andrew Larson January 9, 2025A clinical-stage pharmaceutical company based in Essex, Thetis Pharmaceuticals LLC, has secured $9 million in funding in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust.
Andrew Larson January 9, 2025
Today's Poll
Powered by UHY
Business planners and tax professionals are keeping a close eye on whether federal tax cuts approved during the first Trump administration will be extended before they expire at the end of the year.
The Tax Cut and Jobs Act was approved by Congress in 2017, and signed into law by President Donald Trump in January 2018, during his first term.
The possible extension could reduce taxes for many Americans, but may also increase the federal deficit by $4.5 trillion over the next decade.
2025 Charity Event Guide
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn more
Subscribe
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Subscribe
2025 Book of Lists
Delivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
-
2025 Charity Event Guide
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
-
Subscribe
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
-
2025 Book of Lists
Delivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
ABOUT
ADVERTISE
NEW ENGLAND BUSINESS MEDIA SITES
No articles left
Get access now
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy